+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Investigation Report on China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2021-2025

  • PDF Icon

    Report

  • 50 Pages
  • May 2021
  • Region: China
  • China Research & Intelligence
  • ID: 5336051
Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) is an effective drug for the prevention and treatment of neutropenia or deficiency caused by tumor radiotherapy or chemotherapy. Its product was first developed by Amgen in the United States. In 2012, PEG-rhG-CSF was approved in China. By 2020, the main manufacturers of PEG-rhG-CSF in China are Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. and Qilu Pharmaceutical Co., Ltd.





According to the market research, the sales of PEG-rhG-CSF in the Chinese market have increased year by year from 2016 to 2020. Among them, the sales growth in 2017 was the most obvious, from CNY126 million in 2016 to CNY449 million in 2017, with an annual growth rate of 256.08%. The main reason for the sharp increase is that PEG-rhG-CSF was included in China Medical Insurance in 2017 and the approval of indication was leukemia. The price reduction led to a large increase in sales. The CAGR of sales of PEG-rhG-CSF is about 97.58% from 2016 to 2020.

The analyst analyzes that the sales volume of PEG-rhG-CSF will keep a growth trend from 2021 to 2025 due to the rapid increase in the number of patients. In China, about 40,000 leukemia patients are newly diagnosed every year. This situation led to a growth in the sales volume of PEG-rhG-CSF, which has the advantages of convenience, stability, high efficiency, and approval of indications. In addition, due to the use of PEG-rhG-CSF for non-medullary malignant tumors, the number of indications approved for China's medical insurance is likely to rise, and the sales and the sales volume will also have the potential to grow.

Topics Covered:

  • The impact of COVID-19 on China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
  • Sales value of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2016-2020
  • Competitive landscape of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
  • Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China
  • Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
  • Prospect of China's Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market from 2021 to 2025
Frequently Asked Questions about the Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor(PEG-rhG-CSF) Market

What is the estimated value of the Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor(PEG-rhG-CSF) Market?

The Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor(PEG-rhG-CSF) Market was estimated to be valued at CNY 125.97 Million in 2016.

What is the growth rate of the Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor(PEG-rhG-CSF) Market?

The growth rate of the Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor(PEG-rhG-CSF) Market is 42.7%, with an estimated value of CNY 3091.52 Million by 2025.

What is the forecasted size of the Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor(PEG-rhG-CSF) Market?

The Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor(PEG-rhG-CSF) Market is estimated to be worth CNY 3091.52 Million by 2025.

Who are the key companies in the Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor(PEG-rhG-CSF) Market?

Key companies in the Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor(PEG-rhG-CSF) Market include and Qilu Pharmaceutical Co., Ltd.

Table of Contents

1 Relevant Concepts of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF)
1.1 Indications for Pegylated Recombinant Human Granulocyte Colony Stimulating Factor
1.2 Development of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China
1.3 Governmental Approval of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China
1.4 The Impact of COVID-19 on Pegylated Recombinant Human Granulocyte Colony Stimulating Factor sales in China
2 Sales of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China, 2016-2020
2.1 Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor
2.1.1 Overall Sales Value
2.1.2 Sales Value by Regions
2.2 Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 Sales of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor by Dosage Form in China, 2016-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales Volume
3.2 Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Jinyouli (Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd.'s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor) in China
3.3 Qilu Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Xinruibai (Qilu Pharmaceutical Co., Ltd.'s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor) in China
4 Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor for Different Manufacturers in China, 2020-2021
4.1 Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. (Yinish)
4.2 Qilu Pharmaceutical Co., Ltd. (Xinruibai)
5 Prospect of Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market, 2021-2025
5.1 Influential Factors of Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Development
5.1.1 The Impact of COVID-19 on Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection Registration in China
Chart Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection over the World
Chart Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China, 2016-2020
Chart Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China by Regions, 2016-2020
Chart Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China, 2016-2020
Chart Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China by Regions, 2016-2020
Chart Market Share by Sales Value of Top Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Manufacturers in China, 2016-2020
Chart Sales Value and Volume of Yinish in China, 2016-2020
Chart Sales Value and Volume of Xinruibai in China, 2016-2020
Chart Referential Prices of Yinish in China by Regions, 2020-2021
Chart Referential Prices of Xinruibai in China by Regions, 2020-2021
Chart Forecast on Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China, 2021-2025
Chart Forecast on Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China, 2021-2025

Samples

Loading
LOADING...

Companies Mentioned

  • Shiyao Group Baike biopharmaceutical Co., Ltd.
  • Qilu Pharmaceutical Co., Ltd

Methodology

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...